CHRSCoherus Oncology, Inc.同业对比
Coherus Oncology, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHRS本股 | $192M#6 | — | 3.1x#6 | 4.5x#3 | 59.8%#2 | 489.4%#1 | -429.5%#6 | 276.2%#2 | -351.2%#3 | — | -8.5%#6 | — |
| PLX | $218M#3 | 11.7x#1 | 3.0x#5 | 4.1x#2 | -1.2%#3 | -325.2%#13 | -10.4%#1 | -9.2%#3 | -12.3%#1 | 3#1 | 46.7%#2 | — |
| IVVD | $220M#2 | — | 1.2x#2 | 4.1x#1 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#4 | — | — | -35.5%#9 | — |
| AVXL | $225M#1 | — | 2.0x#3 | — | — | -7.8%#7 | — | -41.2%#6 | — | — | -72.3%#14 | — |
| ALEC | $206M#4 | — | — | 9.8x#6 | -79.1%#7 | -20.2%#9 | -741.3%#7 | — | — | — | -37.4%#10 | — |
| SRZN | $200M#5 | — | — | 57.6x#8 | -67.4%#6 | -280.8%#12 | -1210.6%#8 | — | — | — | 43.9%#3 | — |
| ACOG | $189M#7 | — | 3.6x#9 | 18.5x#7 | — | -39.8%#10 | -221.7%#4 | -39.0%#5 | — | — | 4.1%#5 | — |
| VYGR | $186M#8 | — | 1.2x#1 | 4.6x#4 | -49.5%#4 | -84.2%#11 | -326.6%#5 | -77.6%#7 | — | — | -29.2%#7 | — |
| ABOS | $185M#9 | — | 3.2x#7 | — | — | -18.6%#8 | — | -211.9%#11 | -421.4%#4 | — | 103.6%#1 | — |
| DTIL | $177M#10 | — | 3.9x#10 | 5.2x#5 | -50.1%#5 | -738.0%#14 | -152.2%#3 | -101.0%#8 | — | — | 41.0%#4 | — |
| OTLK | $167M#11 | — | — | 118.3x#10 | — | 17.2%#5 | -4744.3%#9 | — | -12.8%#2 | — | -33.3%#8 | — |
| HUMA | $159M#12 | — | 5.1x#11 | 77.9x#9 | — | 72.5%#2 | -5306.0%#10 | -130.6%#10 | — | — | -62.7%#13 | — |
| ARMP | $155M#13 | — | — | — | — | -818.8%#15 | — | — | — | — | — | 0.1%#1 |
| TNYA | $151M#14 | — | 2.2x#4 | — | — | 18.5%#4 | — | -130.5%#9 | — | — | -45.0%#11 | — |
| NMRA | $144M#15 | — | 3.2x#8 | — | — | -2.8%#6 | — | 532.2%#1 | -594.0%#5 | — | -46.3%#12 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议